Keros Therapeutics, Inc.
NASDAQ: KROS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jasbir S. Seehra
- Employees
- 163
- Headquarters
- Lexington, United States
- IPO year
- 2020
- Market cap
- $349.4M
- Website
- https://www.kerostx.com
Loading KROS…
Loading profile data…Frequently asked questions about KROS
What does Keros Therapeutics, Inc. (KROS) do?
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address...
Where does KROS trade?
Keros Therapeutics, Inc. (KROS) trades on the NASDAQ Global Market.
What sector is KROS in?
Keros Therapeutics, Inc. (KROS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Keros Therapeutics, Inc.?
Jasbir S. Seehra is the chief executive officer of Keros Therapeutics, Inc. (KROS).
Where is Keros Therapeutics, Inc. headquartered?
Keros Therapeutics, Inc. is headquartered in United States.
Does KROS pay a dividend?
Keros Therapeutics, Inc. (KROS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KROS go public?
Keros Therapeutics, Inc. (KROS) completed its initial public offering in 2020.